Company Deep Dive
Read the full research report: business segments breakdown, earnings transcripts review, management credibility analysis, competitive landscape, and scenarios.
N1VO34.SA
Strong BuyNovo Nordisk A/S · Healthcare · Denmark · $210.5B · Avg Vol: $137K/d
98
StockRankGet insider-trade alerts
Q
78
V
75
M
61
P/E (TTM)
11.5x
ROE
59.8%
D/E
0.6x
Dividend %
2.7%
COMPANY DESCRIPTION
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease.
FINANCIAL SUMMARY (BRL)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 142.8B | 187.4B | 234.3B | 249.4B | 20.4% | 267.5B | 241.3B | 245.5B | -0.8% |
| EPS (BRL) | 0.21 | 0.31 | 0.38 | 0.39 | 22.9% | 2.67 | — | — | — |
| Shares | 26.8B | 26.8B | 26.8B | 26.8B | 0.0% | 26.8B | — | — | — |
| Debt | 20.8B | 21.8B | 82.9B | 105.7B | 71.9% | 113.8B | — | — | — |
| Equity | 67.4B | 86.0B | 115.8B | 156.6B | 32.5% | — | — | — | — |
| Op CF | 63.7B | 87.9B | 97.6B | 96.1B | 14.7% | 107.1B | — | — | — |
| Inv CF | -20.1B | -35.4B | -104.0B | -63.9B | — | — | — | — | — |
| Fin CF | -41.8B | -51.0B | 7.0B | -22.9B | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)-5.6%
SMA 50SMA 200
Close
$5.68
RSI (14)
47.2
52W High
$7.89
From 52W High
0.7%
SCORE BREAKDOWN
Quality
78
ROIC
45.7%98.8
ROE
59.8%97.9
GP/Assets
49.7%86.5
Op. Margin
42.5%96.9
FCF/Assets
8.8%83.1
Piotroski
376.5
Int. Cover
32.0x75.6
D/E Ratio
0.63x25.3
Current Ratio
0.87x7.9
Value
75
P/E (TTM)
11.5x84.7
EV/EBITDA
1.6x98.9
P/FCF
28.2x47.9
P/B
0.9x85.8
P/S
4.1x48.8
Div Yield
2.7%62.4
Momentum
61
52W High %
72%52.2
RS 6M
31%86.1
SMA 50/200
1.03x67.0
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
-21%22.7
FUNDAMENTALS
Market Cap
$210.5B
P/E (Forward)
—
Gross Margin
82.0%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of N1VO34.SA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| N1VO34.SA | Novo Nordisk A/S(you) | $210.5B | 98 | Strong Buy |
| AMG.DE | Amgen Inc. | $238.5B | 93 | Strong Buy |
| PFIZ34.SA | Pfizer Inc. | $161.7B | 95 | Strong Buy |
| BMY | Bristol-Myers Squibb Company | $137.4B | 99 | Strong Buy |
| SNY | Sanofi | $109.5B | 97 | Strong Buy |
| GILD.MX | Gilead Sciences, Inc. | $181.0B | 84 | Strong Buy |
| MRK.MX | Merck & Co., Inc. | $372.4B | 91 | Strong Buy |
| NOVN.SW | Novartis AG | $299.9B | 86 | Strong Buy |
| ABBV.MX | AbbVie Inc. | $468.4B | 94 | Strong Buy |
| ROP.SW | Roche Holding AG | $367.3B | 88 | Strong Buy |
Peer medians: ROE 1.9% · P/E 24.0x · Gross margin 52.2%